

## Kaposi Sarcoma: Another Cause of Secondary Lymphedema

### Kaposi Sarkomu: Sekonder Lenfödemin Diğer Bir Nedeni

<sup>1</sup> Selda ÇİFTÇİ İNCEOĞLU<sup>a</sup>, <sup>2</sup> Aylin AYYILDIZ<sup>b</sup>, <sup>3</sup> Banu KURAN<sup>a</sup>

<sup>a</sup>Health Sciences University, Faculty of Medicine, Şişli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation, İstanbul, Türkiye

<sup>b</sup>İstanbul Başakşehir Çam and Sakura City Hospital, Clinic of Physical Medicine and Rehabilitation, İstanbul, Türkiye

**Keywords:** Kaposi sarcoma, lymphedema, secondary lymphedema

**Anahtar Kelimeler:** Kaposi sarkomu; lenfödem; sekonder lenfödem

Dear Editor,

Lymphedema due to Kaposi sarcoma (KS) is a clinical condition that should be included in the differential diagnosis of secondary lymphedema. A case referred to our clinic from dermatology due to lymphedema and previously evaluated for KS due to skin lesions drew our attention to this issue. There is limited information about lymphedema in publications on KS from our country. Therefore, we prepared this letter to emphasize that Kaposi sarcoma should be included in the differential diagnosis of secondary lymphedema and to share this perspective with our colleagues.

KS is a sarcoma caused by Human Herpes Virus-8 (HHV-8), and can present with various subtypes, some of which may be associated with lymphedema. It is classified into 4 groups: classic, endemic, epidemic (associated with Human Immunodeficiency Virus) and iatrogenic type (typically oc-

curing after transplantation).<sup>1</sup> HHV-8 has a tropism for lymphatic endothelial vessels, causing multicentric lymphatic endothelial proliferation and obstruction.<sup>2</sup> Furthermore, the progression of lesions may lead to external obstruction of lymphatic vessels. Lymphedema resulting from lymphatic vascular obstruction usually affects the lower extremities and may develop before, simultaneously with, or after the skin lesion of KS.<sup>1</sup>

Skin lesions on the extremities with lymphedema are crucial in the differential diagnosis. Skin lesions of KS usually appear as purple or brown macules, papules, or hyperkeratotic plaques. They are usually seen on the lower extremities and especially on the feet.<sup>1</sup> The sudden appearance of purplish lesions on a lymphedematous extremity may indicate angiosarcoma, which is a rare but highly aggressive malignancy.<sup>3</sup> In addition to angiosarcoma, melanoma, KS, basal cell carcinoma, or squamous cell carcinoma may develop in the chronic

**Correspondence:** Selda ÇİFTÇİ İNCEOĞLU

Health Sciences University, Faculty of Medicine, Şişli Hamidiye Etfal Training and Research Hospital, Department of Physical Medicine and Rehabilitation, İstanbul, Türkiye

**E-mail:** seldavd@gmail.com



Peer review under responsibility of Journal of Physical Medicine and Rehabilitation Science.

**Received:** 03 Mar 2025

**Accepted:** 17 Mar 2025

**Available online:** 25 Mar 2025

lymphedematous extremity.<sup>4</sup> In other words, KS can be both a cause and a consequence of lymphedema. Telangiectasis, hyperpigmentation, lipodermatosclerosis, and ulcers may also develop due to chronic venous insufficiency and may present as phlebolymphe<sup>5</sup> A skin biopsy is essential for diagnosis, as it directly influences the treatment approach. While complete decongestive therapy (CDT) is applied in cases of lymphedema secondary to KS or chronic venous insufficiency, CDT is not recommended for Stewart-Traves Syndrome which requires surgical treatment.<sup>1,3,5</sup>

In our case, histopathological examination did not confirm KS; instead, the patient was diagnosed with secondary lymphedema due to a history of trauma and recurrent infections. CDT was initiated, resulting in improved peripheral measurements and symptomatic relief. The patient is currently being followed up with a compression garment. We believe

that the experience gained from this KS-related lymphedema case will contribute to our colleagues' understanding of the differential diagnosis in similar cases.

#### **Source of Finance**

*During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.*

#### **Conflict of Interest**

*No conflicts of interest between the authors and / or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.*

#### **Authorship Contributions**

*All authors contributed equally while this study preparing.*

## REFERENCES

1. Dauguet M, Lebbé C, Vignes S. Lymphedema and Kaposi sarcoma: A narrative review. *J Med Vasc.* 2023;48:181-7. PMID: 38035924.
2. Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. *Nat Genet.* 2004;36:687-93. PMID: 15220918.
3. Farhat MM, Le Guern A, Peugniez C, et al. Angiosarcome sur lymphoedème primaire du membre inférieur : une complication rare [Angiosarcoma in primary lymphoedema: A rare complication]. *Ann Dermatol Venerol.* 2018;145:266-9. French. PMID: 29530502.
4. Kim PJ, Mufti A, Sachdeva M, et al. Stewart-Treves syndrome and other cutaneous malignancies in the context of chronic lymphedema: a systematic review. *Int J Dermatol.* 2022;61:62-70. PMID: 34196958.
5. Farrow W. Phlebolymphe<sup>5</sup> A common underdiagnosed and undertreated problem in the wound care clinic. *J Am Col Certif Wound Spec.* 2010;2:14-23. PMID: 24527138; PMCID: PMC3601853.